Longeveron (LGVN) Free Cash Flow (2020 - 2026)
Longeveron (LGVN) posted quarterly Free Cash Flow of -$4.4 million for Q1 2026, up 7.49% year-over-year from -$4.1 million in Q1 2025, and up 17.48% quarter-over-quarter from -$5.3 million in Q4 2025.
Longeveron (LGVN) Free Cash Flow (2020 - 2026) Analysis & Trends
Longeveron's Free Cash Flow history runs 7 years deep, the most recent figure standing at -$4.4 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 7.49% year-over-year to -$4.4 million; the TTM figure through Mar 2026 stood at -$18.5 million (down 14.81% YoY), while the FY2025 annual figure was -$18.9 million, down 30.07% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$4.4 million, up from -$5.3 million in the prior quarter.
- The five-year high for Free Cash Flow was -$2.4 million in Q4 2022, with the low at -$5.9 million in Q1 2023.
- The 5-year median for Free Cash Flow is -$4.4 million (2026), against an average of -$4.2 million.
- The sharpest annual moves came in 2022 and 2024: Free Cash Flow sank 94.52% in 2022, then soared 47.33% in 2024.
- Longeveron's Free Cash Flow stood at -$2.4 million in 2022, then sank by 75.27% to -$4.2 million in 2023, then increased by 18.63% to -$3.4 million in 2024, then plunged by 56.41% to -$5.3 million in 2025, then increased by 17.48% to -$4.4 million in 2026.
- Business Quant data shows LGVN's Free Cash Flow at -$4.4 million in Q1 2026, -$5.3 million in Q4 2025, and -$5.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | -5.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.76 Mn |
| Jun 30, 2026 | -5.76 Mn |
| Mar 31, 2026 | -4.37 Mn |
| Mar 31, 2026 | -4.37 Mn |
| Dec 31, 2025 | -5.30 Mn |
| Dec 31, 2025 | -5.30 Mn |
| Sep 30, 2025 | -5.11 Mn |
| Sep 30, 2025 | -5.11 Mn |
| Jun 30, 2025 | -3.76 Mn |
| Jun 30, 2025 | -3.76 Mn |
| Mar 31, 2025 | -4.72 Mn |
| Mar 31, 2025 | -4.72 Mn |
| Dec 31, 2024 | -3.39 Mn |
| Dec 31, 2024 | -3.39 Mn |
| Sep 30, 2024 | -3.27 Mn |
| Sep 30, 2024 | -3.27 Mn |
| Jun 30, 2024 | -4.76 Mn |
| Jun 30, 2024 | -4.76 Mn |
| Mar 31, 2024 | -3.10 Mn |
| Mar 31, 2024 | -3.10 Mn |